Brief: Vertex Announces Marketing Authorization In Canada For Alyftrek
22/07/2025 19:46
July 23 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES MARKETING AUTHORIZATION IN CANADA FOR ALYFTREK, A ONCE-DAILY NEXT-GENERATION CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS Source text: ID:nCNWHMvvHa Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31